OS Therapies, a clinical-stage immunotherapy and Antibody Drug Conjugate (ADC) biopharmaceutical company, announced that it has completed the acquisition of Advaxis Immunotherapies’ listeria-based cancer immunotherapy assets from Ayala Pharmaceuticals.
Now, the company is positioned as the world leader in listeria-based cancer immunotherapies and is prepared to become a new commercial category of immunotherapy in oncology upon approval of the company’s lead asset OST-HER2 in the prevention of recurrence in fully resected, lung metastatic osteosarcoma, targeted for year-end 2025. New manufacturing-based intellectual property protects the listeria-based immunotherapy platform and cancer immunotherapy candidates through 2040.
Clinical-stage Cancer Immunotherapy Programs Acquired
1.) OST-AXAL (previously AXAL/ADXS/HPV) for Human Papilloma Virus (HPV) associated cancers completed 1st (AIM2CERV) of 2 Phase 3 trials
2.) OST-503 (previously ADXS-503) for Non-Small Cell Lung Cancer (NSCLC) & Glioblastoma reported positive Phase 2 data in NSCLC
3.) OST-PSA (previously ADXS-504/ADXS31142) for Prostate Cancer.
Pre-clinical Cancer Immunotherapy Programs Acquired
1.) 8 unnamed OST-HOT Listeria constructs designed for off-the-shelf treatment of common cancers with shared hotspot mutations and cancer-testis antigen targets.
KEY QUOTES:
“We are thrilled to have now consolidated all of the intellectual property for the listeria cancer immunotherapy platform into OS Therapies, positioning us to fully expand it in the years ahead and improve the standard of care across cancer treatment in the years ahead. We now have late-stage, mid-stage and early-stage cancer immunotherapy candidates, a rich pipeline of preclinical cancer immunotherapy candidates and a long IP runway to in order to fully leverage this powerful cancer immunotherapy platform.”
– Paul Romness, CEO of OS Therapies
“The listeria cancer immunotherapy platform holds tremendous potential to improve the outcomes for cancer patients worldwide. Immune-checkpoint inhibitors have revolutionized cancer treatment in settings where tumor antigens have generated a sufficient T cell response. However, in many cancers these treatments don’t help because T cell responses against key tumor antigens have not developed. The OST Listeria platform specifically delivers relevant cancer targets directly to the immune system and generates new T cell responses that can be used to fight these cancers and help eliminate metastases. With OST-HER2 and the rest of the listeria platform, we have the potential to generate novel, more potent immune and targeted immune responses against solid tumors, metastatic disease and micro metastases from early-stage to late-stage cancers. I am thrilled to be able to guide the OST-HER2 asset through approval in osteosarcoma, and then fully explore that listeria platform’s potential to improve treatment outcomes for cancer patients.”
– Dr. Robert Petit, Chief Medical & Scientific Officer of OS Therapies
